Discovering and developing soloMER™s for the treatment of auto-immune mediated, inflammatory diseases.

Elasmogen Ltd is a biologics company that was spun out of the University of Aberdeen and has developed a proprietary ‘soloMER’ platform.

Specifically, the Company’s technology comprises a platform exploiting the power of biologics as drugs in small, simple and stable formats (‘soloMERs’).  Specifically, they are small (i.e. 9% of the size of a human antibody) and highly stable proteins, making them ideal for both site-specific delivery and the penetration of solid cancerous tumours.

  • Product

    Life Sciences EIS

  • Sector

    Drug discovery

  • Status

    Closed

  • HMRC

    Advanced Assurance

http://www.elasmogen.com/